Matthew J. Armstrong, Leon A. Adams, Ali Canbay, Wing‐Kin Syn – 3 September 2013 – Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, and is strongly associated with the metabolic syndrome. In the last decade, it has become apparent that the clinical burden of NAFLD is not restricted to liver‐related morbidity or mortality, and the majority of deaths in NAFLD patients are related to cardiovascular disease (CVD) and cancer.

Chiun Hsu, Hsiao‐Hui Tsou, Shyh‐Jer Lin, Ming‐Chung Wang, Ming Yao, Wen‐Li Hwang, Woei‐Yau Kao, Chang‐Fang Chiu, Sheng‐Fung Lin, Johnson Lin, Cheng‐Shyong Chang, Hwei‐Fang Tien, Tsang‐Wu Liu, Pei‐Jer Chen, Ann‐Lii Cheng, on behalf of the Taiwan Cooperative Oncology Group – 3 September 2013 – Fatal hepatitis B virus (HBV) reactivation in lymphoma patients with “resolved” HBV infection (hepatitis B surface antigen [HBsAg] negative and hepatitis B core antibody [anti‐HBc] positive) can occur, but the true incidence and severity remain unclear.

Tobias Flecken, Nathalie Schmidt, Sandra Hild, Emma Gostick, Oliver Drognitz, Robert Zeiser, Peter Schemmer, Helge Bruns, Thomas Eiermann, David A. Price, Hubert E. Blum, Christoph Neumann‐Haefelin, Robert Thimme – 3 September 2013 – Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide with a poor prognosis and limited therapeutic options. To aid the development of novel immunological interventions, we studied the breadth, frequency, and tumor‐infiltration of naturally occurring CD8+ T‐cell responses targeting several tumor‐associated antigens (TAA).

Pooja Jha, Thierry Claudel, Anna Baghdasaryan, Michaela Mueller, Emina Halilbasic, Suman K. Das, Achim Lass, Robert Zimmermann, Rudolf Zechner, Gerald Hoefler, Michael Trauner – 3 September 2013 – Hepatic inflammation is a key feature of progressive liver disease. Alterations of fatty acid (FA) metabolism and signaling may play an important role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and its progression to nonalcoholic steatohepatitis (NASH).

Benjamin Goeppert, Carolin Konermann, Christopher Roman Schmidt, Olga Bogatyrova, Lea Geiselhart, Christina Ernst, Lei Gu, Natalia Becker, Manuela Zucknick, Arianeb Mehrabi, Mohammadreza Hafezi, Frederick Klauschen, Albrecht Stenzinger, Arne Warth, Kai Breuhahn, Marcus Renner, Wilko Weichert, Peter Schirmacher, Christoph Plass, Dieter Weichenhan – 3 September 2013 – The molecular mechanisms underlying the genesis of cholangiocarcinomas (CCs) are poorly understood.

Lei Wang, Xiang Zhang, Lin‐Tao Jia, Si‐Jun Hu, Jing Zhao, Jian‐Dong Yang, Wei‐Hong Wen, Zhe Wang, Tao Wang, Jun Zhao, Rui‐An Wang, Yan‐Ling Meng, Yong‐Zhan Nie, Ke‐Feng Dou, Si‐Yi Chen, Li‐Bo Yao, Dai‐Ming Fan, Rui Zhang, An‐Gang Yang – 3 September 2013 – The MYC oncogene is overexpressed in hepatocellular carcinoma (HCC) and has been associated with widespread microRNA (miRNA) repression; however, the underlying mechanisms are largely unknown.

Marjon Kerkhof, Pieter Honkoop – 3 September 2013

Michael L. Volk – 31 August 2013

Ho Cheol Hong, Soon Young Hwang, Hae Yoon Choi, Hye Jin Yoo, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Dong Seop Choi, Kyung Mook Choi – 31 August 2013 – Previous studies have shown that nonalcoholic fatty liver disease (NAFLD) and sarcopenia may share pathophysiological mechanisms, such as insulin resistance, inflammation, vitamin D deficiency, and decreased physical activity. However, their direct relationship has not been investigated.

Paul C. Adams – 31 August 2013